Haloperidol (Haldol)

Introduced 1967

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Published January 23, 2026•Updated January 23, 2026•Reviewed January 23, 2026

Clinical summary for Haloperidol (Haldol): Haloperidol can calm severe agitation and psychosis fast—sometimes in minutes if given IM/IV. It’s powerful, but it comes with real baggage: movement side effects (stiffness, restlessness, dystonia), QT prolongation risk (especially IV), and rare but life-threatening neuroleptic malignant syndrome. It is not approved for dementia-related psychosis and is linked to increased death risk in elderly patients with dementia-related psychosis.

What It's Used For

Haloperidol is a high-potency antipsychotic used when symptoms are severe and fast control matters—especially psychosis-driven agitation, aggressive behavior in mania, or persistent hallucinations and delusions. It’s not a sleep med, not an anxiety med, and it’s not approved for dementia-related psychosis.

Primary Indications

Schizophrenia and other psychotic disorders: Hallucinations, delusions, severe disorganization, agitation linked to psychosisAcute agitation/aggression: Rapid calming when psychosis or mania is suspected to be the main driverAcute mania/hypomania: Short-term stabilization when agitation, insomnia, or aggression is extremeTourette syndrome: Tics and vocalizations when benefits outweigh movement-risk tradeoffs

Off-Label Uses

Hyperactive delirium (short-term adjunct use when nonpharmacologic steps fail and safety is at risk)Postpartum psychosis (acute stabilization when oral meds aren’t feasible)

What People Feel

Real-world haloperidol experiences tend to cluster into a few buckets. This is the vibe people describe most often:

Rapid calming (especially IM/IV)

"It didn’t make me happy—just quieter. The chaos shut off."

How Fast It Works

Haloperidol can work quickly for agitation when given IM or IV. Oral dosing is slower and is usually better for ongoing symptom control once the emergency has passed.

IM (short-acting)

Initial calming can start in ~15 minutes; many people are noticeably calmer within ~25–30 minutes

IV (off-label)

Initial sedation may begin in ~3–20 minutes; peak effect around ~30–45 minutes

Oral

Some improvement can show up within days for mania; psychosis relief often builds over 1–2 weeks, with continued gains over 4–6 weeks

Decanoate (long-acting)

Slow onset; peak levels around ~6 days; designed for maintenance, not crisis control

Half-life

Oral ~14–37 hours; decanoate ~21 days (long tail, slow washout)

How Well It Works

Acute calming for severe agitation

Often within minutes to 30 minutes (route-dependent)

vs Not applicable for this medication.

For severe agitation driven by psychosis or mania, haloperidol is one of the classic “works fast” options. IM dosing can calm someone in about 15–30 minutes, and IV (off-label) can act even faster. For schizophrenia, it can reduce hallucinations and delusions, but meaningful improvement usually builds over days to weeks—this isn’t an instant switch-flip for chronic psychosis.

Critical Safety Information

Not approved for dementia-related psychosis. Increased mortality risk in elderly patients with dementia-related psychosis treated with antipsychotics.

→If you develop severe restlessness, jaw/neck tightness, trouble swallowing, or muscle spasms—treat it like urgent and call your clinician or go to the ER.
→If you feel feverish, rigid, confused, or your heart is racing—this can be an emergency (NMS). Seek immediate care.
→If you have a heart rhythm history, fainting, or you take other QT-prolonging meds, your prescriber may need an ECG and electrolyte checks.
→Avoid mixing with other sedatives unless your prescriber is intentionally combining meds and monitoring you.
→This medication is not approved for dementia-related psychosis because of increased death risk in that group.

Side Effects

Most common problems are movement side effects (EPS) and inner restlessness (akathisia). Serious risks include QT prolongation/torsades and neuroleptic malignant syndrome. Hormonal effects (high prolactin) can also show up, especially with ongoing use.

Common Things People Notice

Stiffness, tremor, slowed movement (drug-induced parkinsonism)
Restlessness you can’t ignore (akathisia)
Muscle spasms (acute dystonia—can involve the neck, jaw, eyes, or throat)
Sleepiness, slowed thinking, or feeling emotionally flat
QT prolongation and dangerous arrhythmias (higher risk with IV use and higher doses)
High prolactin symptoms (missed periods, breast changes, sexual side effects)

Common Side Effects

>10% reported in labeling for extrapyramidal reactions and parkinsonism

Extrapyramidal symptoms (EPS)— This is the signature risk with haloperidol. You might notice stiffness, tremor, slowed movement, jaw tightness, or weird muscle pulls. Dystonia can happen early—sometimes after a first dose—especially with injections. If your throat or neck tightens, treat it like urgent.

1% to 10% reported in labeling

Akathisia— Akathisia is not “anxiety.” It’s a body-level need to move—pacing, bouncing a leg, feeling like you can’t sit still. If this happens, tell your prescriber quickly; it’s fixable, and you shouldn’t have to white-knuckle it.

1% to 10% reported in labeling

Drowsiness / sedation— Some people feel sleepy or slowed. Others feel calm but physically heavy. Don’t drive or do high-risk tasks until you know how you respond.

Frequency not defined; clinically relevant with ongoing treatment

Hyperprolactinemia effects— Haloperidol can raise prolactin. Signs include missed periods, breast tenderness, lactation that isn’t postpartum, sexual dysfunction, or fertility issues. If symptoms show up, your clinician may check a prolactin level or switch to a prolactin-sparing option.

<1% to 10% depending on symptom and setting

Orthostatic hypotension / falls— Dizziness when standing and fall risk are more likely in older adults and with parenteral dosing. Standing up slowly and hydration help, but sometimes the dose or med needs adjustment.

⚠️ Serious Side Effects

Neuroleptic malignant syndrome (NMS): fever, severe rigidity, confusion, autonomic instability, elevated CK. MEDICAL EMERGENCY.
Tardive dyskinesia (TD): involuntary movements (often face/tongue) that can become persistent with long-term exposure.
QT prolongation / torsades de pointes / sudden cardiac death: risk rises with IV use, high dose, baseline QTc issues, and low potassium or magnesium.
Severe dystonia involving the airway (laryngeal dystonia/laryngospasm): trouble breathing or swallowing. EMERGENCY.
Blood count problems (rare): leukopenia, neutropenia, thrombocytopenia; higher concern if history of low counts.
Angioedema or severe allergic reactions (rare): swelling of face/lips/tongue, trouble breathing. EMERGENCY.
Temperature dysregulation: heat stroke risk in extreme heat/exertion; rare hypothermia cases also reported.

Critical Drug Interactions

Haloperidol is a QT-risk medication and a dopamine blocker—so interactions often fall into two buckets: heart rhythm risk and movement/neurologic risk. It also has clinically relevant CYP interactions (notably CYP2D6 and CYP3A4).

With: QT-prolonging medications (many antiarrhythmics, certain antibiotics, methadone, some antidepressants, other antipsychotics)

Risk: Additive QT prolongation increases risk of torsades and sudden death—especially with IV haloperidol, high total doses, or electrolyte abnormalities.

Action: Avoid combinations when possible. If unavoidable, use the lowest effective doses, correct potassium/magnesium, and consider ECG monitoring.

With: CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion) and CYP3A4 inhibitors (e.g., certain macrolides/azoles, some HIV meds)

Risk: Higher haloperidol exposure can raise EPS and QT risk.

Action: Monitor closely for EPS, sedation, and ECG changes in higher-risk patients; dose reductions may be needed.

With: CYP3A4 inducers (e.g., carbamazepine, rifampin, St. John’s wort)

Risk: Lower haloperidol levels can reduce efficacy and destabilize psychosis or agitation control.

Action: Avoid if possible. If needed, monitor symptoms and adjust dose carefully.

With: Levodopa and dopamine agonists (Parkinson meds)

Risk: Haloperidol can directly oppose dopamine therapies and worsen Parkinson symptoms; severe EPS risk.

Action: Generally avoid. Haloperidol is contraindicated in Parkinson disease and dementia with Lewy bodies.

With: Other CNS depressants (benzodiazepines, opioids, alcohol, sedating antihistamines)

Risk: Additive sedation, falls, and respiratory risk in medically fragile patients.

Action: Use cautious dosing and clear monitoring plans, especially in older adults or inpatient settings.

With: Lithium

Risk: Neurotoxicity has been reported with antipsychotic + lithium combinations (confusion, rigidity, tremor), and NMS risk may rise in vulnerable patients.

Action: If combined, monitor closely for neurologic changes, hydration status, and rigidity/fever symptoms.

Safe Discontinuation

If haloperidol is being used for ongoing psychiatric treatment (like schizophrenia), don’t stop abruptly unless there’s a serious safety reason. A gradual taper helps you catch early relapse signs and reduces withdrawal-type symptoms (agitation, insomnia, sweating, nausea, restlessness, return of psychosis). For long-acting decanoate injections, withdrawal symptoms are less common because the medication leaves the body slowly—but relapse monitoring still matters.

Key Points

If stopping due to side effects (EPS, QT issues, suspected NMS), your prescriber may switch medications rather than taper slowly—safety comes first.
For stable long-term treatment, taper over weeks to months based on relapse risk, history of repeated episodes, and current stability.
Watch for early warning signs: rising paranoia, sleep collapse, irritability, agitation, social withdrawal, or subtle thought disorganization.
If akathisia or dystonia shows up during taper or switch, tell your prescriber—dose and cross-titration speed may need adjustment.
For decanoate: drug elimination is slow; withdrawal symptoms are uncommon, but symptom recurrence can still happen—monitor closely for several weeks to months.

Dosing Information

Adult Dosing

agitation im iv: IM or IV (off-label route): 2 to 10 mg per dose; may repeat every ≥15 minutes until controlled; once controlled, may repeat every 0.5 to 6 hours as needed; typical maximum 30 mg/day

agitation oral prn: Oral: 2 to 10 mg; may repeat every 6 hours as needed; typical maximum 30 mg/day (some patients may respond to 0.5 to 1 mg starting doses)

delirium non icu: Non-ICU delirium (IM/IV/off-label or oral): 0.5 to 1 mg initially; may repeat every 30 minutes until calm; typical maximum 5 mg/day

delirium icu loading: ICU hyperactive delirium (IM/IV/off-label): Initial bolus based on severity (mild 0.5–2.5 mg; moderate 2–5 mg; severe 10–20 mg); may repeat or increase every 15–30 minutes until calm

delirium icu maintenance: After calm achieved in ICU delirium: maintenance dosing often ~25% of total loading dose every 6–12 hours if needed (individualize and reassess daily)

schizophrenia oral initial: Oral schizophrenia: 1 to 10 mg/day in 1 to 3 divided doses (first-episode or sensitive patients may start lower: 0.5 to 5 mg/day in 1 to 3 divided doses)

schizophrenia titration: Increase based on response and tolerability every 3 to 7 days; monitor closely for akathisia and parkinsonism during titration

schizophrenia maintenance: Usual maintenance: 2 to 20 mg/day in divided doses; aim for the lowest effective dose

schizophrenia max recommended: Doses >30 mg/day are generally not recommended due to tolerability (labeling mentions higher, but side effects rise steeply)

decanoate initial with oral overlap: Decanoate (with oral overlap): First confirm tolerability with short-acting haloperidol. Initial IM decanoate dose is typically 10 to 15 times the daily oral dose. If conversion requires >100 mg, split into 2 injections (max 100 mg first dose, remainder 3–7 days later). Maximum total initial dose 450 mg. Begin maintenance ≤4 weeks after the total initial dose is completed.

decanoate oral overlap taper: Oral overlap taper (with overlap regimen): Starting 1 to 2 months after completion of the initial decanoate dose, taper oral dose gradually (example approach: reduce ~25% each week over ~1 month), adjusting based on symptoms and side effects

decanoate initial without oral overlap: Decanoate (without oral overlap): First confirm tolerability with short-acting haloperidol. Initial loading is typically 20 times the daily oral dose (split injections if >100 mg; max 100 mg first dose; remainder 3–7 days later). Maximum total initial dose 450 mg. Oral haloperidol is typically discontinued after the initial long-acting injection in this approach.

decanoate maintenance: Decanoate maintenance: Often 10 to 15 times the previous daily oral dose (commonly 50 to 200 mg) given at ≤4-week intervals; adjust based on response and tolerability; maximum 450 mg every 4 weeks

mania oral initial: Acute mania/hypomania (off-label): Oral 2 to 15 mg/day in 1 or 2 divided doses (some regimens also use ~0.2 mg/kg/day up to 15 mg/day)

mania titration: Increase by ≤5 mg as frequently as every 2 days based on response and tolerability

mania max: Typical maximum 30 mg/day (higher doses increase EPS and QT risk)

postpartum psychosis im: Postpartum psychosis acute stabilization (IM, off-label): Mild agitation 0.5–2 mg once; moderate 2–5 mg once; severe 10 mg once; may repeat every 30 minutes if needed

tourette oral initial: Tourette syndrome (alternative agent): Oral 1 to 2 mg/day in 1 to 3 divided doses

tourette titration: Increase by 0.5 to 2 mg every 2 to 3 days based on response and tolerability

tourette max: 12 mg/day is a commonly recommended ceiling due to tolerability; higher doses increase movement-risk burden

iv qtc safety: IV safety note (off-label): Avoid single IV doses ≥2 mg in patients with baseline QTc >450 msec or strong QT-risk factors; consider continuous cardiac monitoring during administration and for 2–3 hours after; if QTc >500 msec or increases >60 msec on treatment, reduce dose, change route, or switch antipsychotic

renal adjustment: Kidney impairment: No dosage adjustment usually needed (minimal unchanged renal elimination), but use caution in medically fragile patients

hepatic adjustment: Liver cirrhosis: Consider ≤50% of usual dose for Child-Pugh A/B and ≤25% for Child-Pugh C, then titrate slowly to the lowest effective dose

Simple Explanation

In a crisis (severe agitation), haloperidol is often used in small-to-moderate repeated doses until the person is calm—then the plan shifts to oral or long-acting maintenance if needed. For ongoing psychosis, slower titration and the lowest effective dose help reduce movement side effects and long-term risks. IV use is off-label and comes with extra QT monitoring considerations.

Pregnancy, Breastfeeding, Special Groups

Haloperidol can be used during pregnancy when benefits clearly outweigh risks, especially for severe psychosis or mania where untreated illness is dangerous. Breastfeeding exposure is possible, and infant sedation or feeding problems have been reported. In older adults, the risk profile is tougher: falls, QT issues, and the dementia-related psychosis mortality warning are major concerns.

👶Pregnancy

Haloperidol crosses the placenta. Class-level data for first-generation antipsychotics do not show a clear large increase in major congenital malformations, but individual outcome data are mixed and limited. Third-trimester exposure to antipsychotics can be associated with newborn EPS and/or withdrawal-like symptoms (agitation, abnormal tone, tremor, feeding or breathing difficulties). Do not taper late in pregnancy solely to prevent neonatal symptoms; instead, use the lowest effective dose and avoid polytherapy when possible. Shared decision-making is essential, because untreated psychosis or mania can be high-risk for both parent and baby.

🤱Breastfeeding

Haloperidol is present in breast milk, and infant exposure has been documented. Reports describe possible infant sedation, poor feeding, irritability, and slowed motor movements—especially if other sedating meds are also involved. The manufacturer does not recommend breastfeeding on haloperidol. If breastfeeding continues, monitor the infant closely (alertness, feeding, weight gain, tone, and development), and coordinate with pediatrics. In postpartum psychosis, protecting maternal sleep is part of treatment; some clinicians recommend avoiding overnight breastfeeding during early stabilization.

👧Children & Adolescents (Under 18)

Haloperidol can be used in children for specific indications (including tics and severe agitation), but the movement-risk profile is higher and acute dystonia can be dramatic. Use the lowest effective dose, build slowly, and consider EPS prevention strategies when clinically appropriate. For most pediatric psychiatric conditions, second-generation antipsychotics are often preferred due to tolerability.

👴Older Adults (65+)

High-risk medication in older adults. Avoid for behavioral problems associated with dementia or delirium unless nonpharmacologic approaches have failed and the patient is at risk of harming self or others. Use lower starting doses (often 0.5–1 mg) and titrate slowly. Monitor closely for EPS, falls, orthostasis, QT issues, and sodium changes (SIADH/hyponatremia risk in older adults). Haloperidol is not approved for dementia-related psychosis and is associated with increased mortality in that population.

🔬Liver Impairment

Haloperidol is extensively metabolized in the liver and is highly protein-bound; accumulation is a concern in cirrhosis. For scheduled maintenance indications (schizophrenia/mania), consider reduced initial dosing and slower titration, aiming for the lowest effective dose. QT risk may rise with higher exposure.

💧Kidney Impairment

No routine dose adjustment is typically required because very little unchanged drug is renally eliminated, and haloperidol is unlikely to be dialyzed. Use clinical judgment in medically fragile patients and monitor for side effects.

Clinical Monitoring

EPS every visit: ask about stiffness, tremor, jaw/neck tightness, restlessness; consider formal rating scales when indicated
Tardive dyskinesia surveillance: screen regularly (e.g., AIMS at least annually; more often if high risk)
Akathisia check: pacing, inner restlessness, inability to sit still—treat early to avoid nonadherence and distress
Cardiac monitoring (when indicated): baseline ECG in higher-risk patients; extra caution and ECG/electrolytes monitoring with IV use or higher doses
Electrolytes (K, Mg, Ca) when QT risk is present or when using IV/off-label routes; correct abnormalities aggressively
Vital signs and orthostatics: hypotension, tachycardia; fall risk assessment, especially in older adults
Mental status and functional change: target symptom tracking (psychosis intensity, agitation frequency, sleep stability, safety behaviors)
Metabolic monitoring: weight/BMI and metabolic labs over time (haloperidol tends to be lower metabolic-risk than many SGAs, but risk is not zero)
Prolactin symptom monitoring: menstrual changes, libido/sexual function changes, galactorrhea, gynecomastia; check prolactin level if symptomatic
CBC if clinically indicated: especially if history of low WBC or drug-induced neutropenia; monitor for infection symptoms
Temperature regulation and hydration: watch for heat illness risk in extreme heat/exertion; monitor for unusual hypothermia symptoms in vulnerable patients
Medication adherence and safety: missed doses, overuse, accidental double dosing; careful review of other QT-prolonging or sedating meds

Available Formulations

Oral tablets: 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg
Oral concentrate (as lactate; strength expressed as base): 2 mg/mL
Short-acting injection (as lactate; strength expressed as base): 5 mg/mL
Long-acting IM decanoate suspension (strength expressed as base): 50 mg/mL and 100 mg/mL (IM only; never IV)

Mechanism of Action

Haloperidol mainly works by blocking dopamine D2 receptors in the brain. Dopamine signaling is heavily involved in hallucinations, delusions, and manic agitation. By turning down D2 activity, haloperidol can rapidly reduce psychosis-driven intensity—but that same dopamine blockade is also why movement side effects (EPS) are more common.

Place in Treatment Algorithm

Haloperidol is a “high-control, high-side-effect” antipsychotic. It still has a strong role when you need fast behavioral stabilization (severe agitation, dangerous psychosis, extreme mania) or when a patient has done well on it historically. For many people starting long-term treatment today, second-generation antipsychotics are often preferred first because EPS and tardive dyskinesia risks are generally lower. Haloperidol is also not approved for dementia-related psychosis and should be avoided for behavioral symptoms in dementia unless there’s imminent safety risk and other approaches have failed.

Frequently Asked Questions

What is haloperidol (Haldol) used for in psychiatry?

Haloperidol is used to treat psychosis (hallucinations and delusions), severe agitation when psychosis or mania is driving the behavior, and sometimes acute mania. It can also be used for Tourette syndrome tics. It’s generally not used for everyday anxiety or as a sleep medication.

How fast does haloperidol work?

Route matters. IM haloperidol can start calming severe agitation in about 15 minutes, often with noticeable effect within 25–30 minutes. IV use is off-label but can act within minutes. Oral dosing is slower and is more about ongoing symptom control than immediate sedation.

Why do clinicians worry about movement side effects with haloperidol?

Haloperidol strongly blocks dopamine D2 receptors, which helps psychosis—but also increases the chance of EPS (stiffness, tremor, dystonia) and akathisia (severe inner restlessness). With long-term use, it can also raise the risk of tardive dyskinesia, which can be persistent.

What is akathisia, and how do I know if I have it?

Akathisia feels like you can’t sit still—pacing, leg bouncing, crawling-out-of-your-skin restlessness. People often describe it as unbearable and not the same as anxiety. If it happens, tell your prescriber quickly; dose changes or targeted meds can help.

Does haloperidol affect the heart rhythm (QT prolongation)?

Yes. Haloperidol can prolong QTc and, in rare cases, trigger torsades de pointes (a dangerous arrhythmia). Risk is higher with IV dosing (off-label), high total doses, baseline prolonged QTc, low potassium or magnesium, structural heart disease, and combinations with other QT-prolonging medications.

Is haloperidol safe in older adults with dementia-related psychosis?

It’s not approved for dementia-related psychosis and carries a boxed warning: antipsychotics are associated with increased mortality in elderly patients with dementia-related psychosis. Haloperidol should generally be avoided for behavioral symptoms in dementia unless non-drug options fail and there is imminent risk of harm.

Can haloperidol raise prolactin?

Yes. Haloperidol can increase prolactin, which can cause missed periods, breast tenderness or lactation, sexual dysfunction, and fertility issues. If symptoms show up, clinicians may check a prolactin level or switch to a prolactin-sparing medication.

What’s the difference between Haldol and Haldol Decanoate?

Haldol (oral or short-acting injection) is used for short-term control or flexible dosing. Haldol Decanoate is a long-acting IM injection used for maintenance in schizophrenia, typically given every 4 weeks. Decanoate is not for immediate calming in a crisis and must never be given IV.

Do I need to taper haloperidol if I’m stopping it?

If you’ve been on haloperidol regularly for a while, a gradual taper is usually recommended to reduce rebound symptoms and to catch early relapse signs. If you’re stopping because of a serious adverse reaction (like suspected NMS or dangerous QT changes), the plan may shift to urgent stopping and switching—safety first.

Is haloperidol used for insomnia?

No. Haloperidol can cause sedation, but it’s not an insomnia medication and comes with significant risks (movement side effects, QT prolongation). Using antipsychotics primarily for sleep—especially in older adults—is generally considered poor risk-benefit.

This medication information is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Never take medication without a prescription from a licensed healthcare provider.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists

Haloperidol (Haldol)

Introduced 1967

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Published January 23, 2026•Updated January 23, 2026•Reviewed January 23, 2026